A highly differentiated approach for allogeneic cell therapy
Catamaran harnesses the natural cancer-fighting properties of NK cells, the power of synthetic biology and innovative non-viral cell engineering to create novel CAR-NK cell therapies for the treatment of more patients and more cancer types, especially solid tumors. Learn more
Our TAILWIND® platform is a proprietary and integrated suite of technologies to engineer, expand and process NK cells into safe and highly potent allogeneic CAR-NK cell therapy products.
Innovation in NK cell therapy is the guiding focus of our team
At Catamaran, our guiding focus is to drive innovation in cell therapy to treat more patients. Our scientific founders, Branden Moriarity, PhD and Dr. Catherine Bollard, MD, are pioneers in NK cell biology, engineering, manufacturing and clinical application. Our internal Catamaran team combines its deep expertise in cell therapy with a passion for developing paradigm-shifting therapies. See more about our team